The optimal dose of oral tranexamic acid in melasma: A network meta-analysis.
Wang WJ, Wu TY, Tu YK, Kuo KL, Tsai CY, Chie WC.
Indian J Dermatol Venereol Leprol. 2023 Jan-Mar;89(2):189-194. doi: 10.25259/IJDVL_530_2021.
The Therapeutic Use of Antioxidants for Melasma.
Babbush KM, Babbush RA, Khachemoune A.
J Drugs Dermatol. 2020 Aug 1;19(8):788-792. doi: 10.36849/JDD.2020.5079.
Melasma Treatment: An Evidence-Based Review.
McKesey J, Tovar-Garza A, Pandya AG.
Am J Clin Dermatol. 2020 Apr;21(2):173-225. doi: 10.1007/s40257-019-00488-w.
Future therapies in melasma: What lies ahead?
Sarkar R, Bansal A, Ailawadi P.
Indian J Dermatol Venereol Leprol. 2020 Jan-Feb;86(1):8-17. doi: 10.4103/ijdvl.IJDVL_633_18.
Medical therapies for melasma.
Mahajan VK, Patil A, Blicharz L, Kassir M, Konnikov N, Gold MH, Goldman MP, Galadari H, Goldust M.
J Cosmet Dermatol. 2022 Sep;21(9):3707-3728. doi: 10.1111/jocd.15242. Epub 2022 Jul 31.
Melasma: How hormones can modulate skin pigmentation.
Filoni A, Mariano M, Cameli N.
J Cosmet Dermatol. 2019 Apr;18(2):458-463. doi: 10.1111/jocd.12877. Epub 2019 Feb 18.
Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation.
Ko D, Wang RF, Ozog D, Lim HW, Mohammad TF.
J Am Acad Dermatol. 2023 Feb;88(2):291-320. doi: 10.1016/j.jaad.2021.12.065. Epub 2022 Feb 12.
Acanthosis Nigricans: An Updated Review.
Leung AKC, Lam JM, Barankin B, Leong KF, Hon KL.
Curr Pediatr Rev. 2022;19(1):68-82. doi: 10.2174/1573396318666220429085231.
Low-dose oral isotretinoin for recalcitrant Riehl's melanosis: A retrospective case series.
Kim MJ, Huh CH, Shin JW, Na JI.
J Dtsch Dermatol Ges. 2023 Sep;21(9):1029-1031. doi: 10.1111/ddg.15141. Epub 2023 Jul 19.
Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Wong M, Sade S, Gilbert M, Klieb HB.
Dermatol Online J. 2011 May 15;17(5):4.
